Texas A&M University could take a leading role in producing a COVID-19 vaccine next year if an effort from Novavax Inc. makes it through clinical trials. The federal government will spend $265 million to reserve a manufacturing center at Texas A&M University System to mass produce a COVID-19 vaccine candidate when clinical trials are complete and approval is granted from the U.S. Food and Drug Administration, system officials said Monday.
Read Again https://www.healthleadersmedia.com/innovation/feds-approve-265-million-manufacture-coronavirus-vaccine-texas-am-facilityBagikan Berita Ini
Related Posts :
Zinc Oxide for Cosmetics Market Manufacture Size, Opportunities, developments and Future Forecasts to 2024 - Markets Pioneer- Manufacture Peace, Not war - Kashmir Reader
- Esophageal Cancer Market Manufacture Size, Opportunities, developments and Future Forecasts to 2024 - Markets Pioneer
- India-Russia joint venture to manufacture Kalashnikovs will fulfil needs of security forces: Putin - Hindustan Times
- Made in Amethi, AK-203 to Help Jawans Fight Terrorists: PM Modi at His 1st Rally in RaGa's Bastion - News18
0 Response to "Feds approve $265 million to manufacture coronavirus vaccine at Texas A&M facility - HealthLeaders Media"
Post a Comment